◎ Sugi Atlas

Atlas / Disease / Psychiatric disorder

Psychiatric disorder

disease
On this page

Also known as disease of mental healthmental disordermental dysfunctionmental illnessPsychiatric disease

Summary

Psychiatric disorder (MONDO:0002025) is a disease (an umbrella term covering 14 Mondo subtypes) with 512 GWAS associations across 23 studies and 787 clinical trials. Top therapeutic interventions include brexpiprazole, fluoxetine, and paroxetine. A subtype of disease by developmental or physiological process — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 14 Mondo subtypes
  • GWAS associations: 512
  • Clinical trials: 787

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepsychiatric disorder
Mondo IDMONDO:0002025
MeSHD001523
DOIDDOID:150
NCITC2893
Is cancer (heuristic)no

Also known as: disease of mental health · mental disorder · mental dysfunction · mental illness · Psychiatric disease · Psychiatric disorder

Data availability: 512 GWAS associations (23 studies).

Disease family

An umbrella term covering 14 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder

Related subtypes (11): metabolic disease, premature aging syndrome, disorder of development or morphogenesis, inflammatory disease, disorder of glycosylation, ulcer disease, mitochondrial disease, sleep disorder, perinatal disease, obstetric disorder, disease by molecular mechanism

Subtypes (14): sexual disorder, dissociative disorder, impulse control disorder, personality disorder, cognitive disorder, factitious disorder, substance-related disorder, somatoform disorder, mental disorder, eating disorder, enuresis, Alice in Wonderland syndrome, catatonia, body integrity dysphoria

Genetics & variants

GWAS landscape

512 GWAS associations across 23 studies. Top hits map to 22 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs778006513e-09SLC22A2?
chr8:257393647e-09G5.02
rs3625141e-08GPR53P - OR2I1T1.4
rs768843051e-08TIAM1T5.5
rs767082901e-08TIAM1T5.5
rs127129612e-08PRKCEA1.1
rs22236112e-08LINC01015 - GPR53PA1.39
rs793281543e-08EBF2C4.25
rs47362535e-08COL22A1 - KCNK9T0.87
rs95219457e-08RPL21P107 - LINC00567A1.51
rs9083099e-08SIGLEC22PG2.25
rs619246139e-08LINC02450 - MRPS36P5C1.93
rs66578771e-07VPS13DG1.52
chr10:1191746901e-07CAA3.17
rs733054492e-07CISTRG1.7
rs607714972e-07VPS13DA1.51
rs12334102e-07GPR53P - OR2I1C1.42
rs1408111503e-07GM2AA2.5
rs1458190443e-07RBMS3-AS3, RBMS3C6.85
rs75467944e-07VPS13DC1.59
rs43208294e-07LINC02607 - LINC02790A1.41
rs1136109044e-07LINC01902C2.47
rs576977164e-07PNPLA1G6.7
rs21612764e-07ISCA1P1 - HTR1AT2.92
rs126537224e-07ISCA1P1 - HTR1AT2.92
rs1833133575e-07ZBTB8AA2.08
rs1906289795e-07KIF26BA2.27
rs728666716e-07VPS13DT1.56
rs728666866e-07VPS13DC1.55
rs3986166e-07GPR53P - OR2I1T1.37

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90038600Donertas HM202183,484401,114Common genetic associations between age-related diseases.
GCST90691954Karczewski KJ202539,711369,930Pan-UK Biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effects.
GCST90038641Donertas HM202136,199448,399Common genetic associations between age-related diseases.
GCST90481821Verma A202432,651376,998Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90435881Zhou W201828,791365,476Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90481820Verma A202413,30293,165Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90086128Guindo-Martinez M20218,62448,013The impact of non-additive genetic associations on age-related complex diseases.
GCST90086129Guindo-Martinez M20218,62448,013The impact of non-additive genetic associations on age-related complex diseases.
GCST90086130Guindo-Martinez M20218,62448,013The impact of non-additive genetic associations on age-related complex diseases.
GCST90086131Guindo-Martinez M20218,62448,013The impact of non-additive genetic associations on age-related complex diseases.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic49

MAF distribution

BucketVariants
common (>=0.05)30
low_freq (0.01-0.05)0
rare (<0.01)0
unknown20

Functional consequences

ConsequenceCount
intron_variant32
intergenic_variant10
unknown4
non_coding_transcript_exon_variant1
synonymous_variant1
5_prime_UTR_variant1
mature_miRNA_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs778006516160265799G>A,T0.05intron_variantSLC22A23e-09Tier 4: intronic/intergenic
chr8:257393647e-09Tier 4: intronic/intergenic
rs362514629539533C>A,G,T0.05intergenic_variantGPR53P - OR2I11e-08Tier 4: intronic/intergenic
rs768843052131209915C>G,Tintron_variantTIAM11e-08Tier 4: intronic/intergenic
rs767082902131209710C>Tintron_variantTIAM11e-08Tier 4: intronic/intergenic
rs12712961246051581T>A,C0.452intron_variantPRKCE2e-08Tier 4: intronic/intergenic
rs2223611629536429G>A0.05intergenic_variantLINC01015 - GPR53P2e-08Tier 4: intronic/intergenic
rs79328154825876879T>Cintron_variantEBF23e-08Tier 4: intronic/intergenic
rs47362538139342742C>T0.251intergenic_variantCOL22A1 - KCNK95e-08Tier 4: intronic/intergenic
rs952194513110796027G>A0.05intron_variantRPL21P107 - LINC005677e-08Tier 4: intronic/intergenic
rs9083091951211510C>G,Tnon_coding_transcript_exon_variantSIGLEC22P9e-08Tier 4: intronic/intergenic
rs619246131242928687A>C0.05intron_variantLINC02450 - MRPS36P59e-08Tier 4: intronic/intergenic
rs6657877112260892T>G0.05intron_variantVPS13D1e-07Tier 4: intronic/intergenic
chr10:1191746901e-07Tier 4: intronic/intergenic
rs733054491253742360A>G0.05intron_variantCISTR2e-07Tier 4: intronic/intergenic
rs60771497112260216G>A0.05intron_variantVPS13D2e-07Tier 4: intronic/intergenic
rs1233410629547717T>A,C0.05intergenic_variantGPR53P - OR2I12e-07Tier 4: intronic/intergenic
rs1408111505151250621G>Aintron_variantGM2A3e-07Tier 4: intronic/intergenic
rs145819044329272766T>C,Gintron_variantRBMS3-AS3, RBMS33e-07Tier 4: intronic/intergenic
rs7546794112276090T>C0.05synonymous_variantVPS13D4e-07Tier 4: intronic/intergenic
rs4320829195794964T>A,G0.05intergenic_variantLINC02607 - LINC027904e-07Tier 4: intronic/intergenic
rs1136109041839823827T>Cintron_variantLINC019024e-07Tier 4: intronic/intergenic
rs57697716636264953A>G0.05intron_variantPNPLA14e-07Tier 4: intronic/intergenic
rs2161276563451319C>T0.05intergenic_variantISCA1P1 - HTR1A4e-07Tier 4: intronic/intergenic
rs12653722563452642C>T0.05intergenic_variantISCA1P1 - HTR1A4e-07Tier 4: intronic/intergenic
rs183313357132546455T>A0.05intron_variantZBTB8A5e-07Tier 4: intronic/intergenic
rs1906289791245431603C>Aintron_variantKIF26B5e-07Tier 4: intronic/intergenic
rs72866671112324673C>T0.05intron_variantVPS13D6e-07Tier 4: intronic/intergenic
rs72866686112332948T>C0.05intron_variantVPS13D6e-07Tier 4: intronic/intergenic
rs398616629546453C>T0.05intergenic_variantGPR53P - OR2I16e-07Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
OxazepamApproved (phase 4)
MeropenemPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Oxytocin, Psilocybin.

Clinical trials & evidence

Clinical trials

Clinical trials: 787.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified680
PHASE230
PHASE324
PHASE419
PHASE117
PHASE2/PHASE39
EARLY_PHASE15
PHASE1/PHASE23

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04289142PHASE4RECRUITINGCognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
NCT06534047PHASE4RECRUITINGTranscranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial
NCT06754163PHASE4ACTIVE_NOT_RECRUITINGEvaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
NCT00001658PHASE4COMPLETEDAmoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
NCT00145847PHASE4COMPLETEDNaltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00259883PHASE4COMPLETEDCombination Of PAXIL Tablet And Benzodiazepines
NCT00283270PHASE4COMPLETEDEffectiveness of Screening and Counselling for Elderly With Psychological Problems
NCT00288782PHASE4COMPLETEDPET Neuroimaging of [11C]Mirtazapine
NCT01182012PHASE4UNKNOWNReduction of Cardiovascular Risk in Severe Mental Illness
NCT01783912PHASE4COMPLETEDHelping Those With Mental Illness Quit Smoking
NCT02022709PHASE4COMPLETEDEfficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
NCT03216941PHASE4COMPLETEDRandomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward
NCT03655847PHASE4UNKNOWNAcceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection
NCT03809897PHASE4WITHDRAWNVarenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders
NCT03830398PHASE4UNKNOWNComparison of Drugs on Headache Treatment After ECT Treatment
NCT03907124PHASE4WITHDRAWNClinical Utility of Pharmacogenomics of Psychotropic Medications
NCT03950427PHASE4COMPLETEDPARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness
NCT04781998PHASE4COMPLETEDIs Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?
NCT05583240PHASE4UNKNOWNInfluence of Olfaction Essential Oils on the Consumption of Benzodiazepine Receptor Agonists & Z-Drugs (BZRAs) Prescribed as if Needed in Psychiatric Outpatients (HECBA-PSY).
NCT05508789PHASE3ACTIVE_NOT_RECRUITINGA Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ 5)
NCT05738486PHASE3ACTIVE_NOT_RECRUITINGA Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 6)
NCT05946486PHASE3NOT_YET_RECRUITINGEvaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.
NCT06062953PHASE2/PHASE3RECRUITINGEfficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia
NCT06387290PHASE3RECRUITINGOptimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
NCT07497711PHASE2/PHASE3RECRUITINGVirtual Menstrual Pain Approaches in Females
NCT00034762PHASE3COMPLETEDEfficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer’s Disease
NCT00034892PHASE3COMPLETEDCAFE Comparison of Atypicals in First Episode of Psychosis
NCT00035802PHASE3COMPLETEDA Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
NCT00183313PHASE3COMPLETEDImproving Primary Care in Patients With Mental Disorders
NCT00183716PHASE3COMPLETEDThe Trauma Recovery and Empowerment Model for Treating Post-Traumatic Stress Disorder in Women
NCT00216502PHASE3COMPLETEDA Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer’s Disease
NCT00240695PHASE3COMPLETEDA Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
NCT00260013PHASE2/PHASE3COMPLETEDTransition Into Primary-care Psychiatry (TIPP)
NCT00561574PHASE3COMPLETEDA Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
NCT00561821PHASE3COMPLETEDEfficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
NCT00631657PHASE3COMPLETEDA 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
NCT00692081PHASE2/PHASE3COMPLETEDSocial Competence Training for Adolescents With Borderline Intellectual Functioning
NCT00750919PHASE3TERMINATEDTwenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
NCT00942097PHASE2/PHASE3COMPLETEDHomeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder
NCT01201187PHASE3COMPLETEDEfficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BREXPIPRAZOLE48
FLUOXETINE46
PAROXETINE44
PRUCALOPRIDE44
BUPROPION43
CITALOPRAM43
FLUVOXAMINE43
NICOTINE43
DONANEMAB42
GALANTAMINE HYDROBROMIDE42
GANAXOLONE42
VARENICLINE42
AMOXICILLIN41
FLORBETABEN F1841
KETAMINE41
LAMOTRIGINE41
LEMBOREXANT41
MIRTAZAPINE41
OLIVE OIL41
PALIPERIDONE PALMITATE41
QUETIAPINE FUMARATE41
ROTIGOTINE41
SERTRALINE41
TOPIRAMATE41
TROMETHAMINE41
ZOPICLONE41
ESMIRTAZAPINE35
CYTISINICLINE31
LEUCINE31
OMEGA-3 FATTY ACIDS31

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 18

This page pulls from 18 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncmeshmimmondomondochildmondoparentncitorphanet